Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -85,284 | -42,607 | -190,886 | -152,076 | -110,676 |
| Depreciation Amortization | 3,316 | 1,984 | 8,138 | 5,902 | 3,728 |
| Accounts payable and accrued liabilities | 1,694 | 663 | -1,231 | -1,830 | -758 |
| Other Working Capital | 18,840 | 18,371 | -10,877 | -10,675 | -10,530 |
| Other Operating Activity | 16,525 | 8,676 | 45,610 | 37,032 | 26,277 |
| Operating Cash Flow | $-44,909 | $-12,913 | $-149,246 | $-121,647 | $-91,959 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -159 | -9 | -386 | -386 | -143 |
| Purchase Of Investment | -285,415 | -101,694 | -138,257 | -109,880 | -60,146 |
| Sale Of Investment | 108,427 | 72,115 | 234,202 | 172,212 | 110,300 |
| Investing Cash Flow | $-177,147 | $-29,588 | $95,559 | $61,946 | $50,011 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 208,994 | 21,122 | 23,249 | 15,390 | 12,154 |
| Other Financing Activity | 0 | 0 | 6,908 | 6,908 | 6,908 |
| Financing Cash Flow | $208,994 | $21,122 | $30,157 | $22,298 | $19,062 |
| Beginning Cash Position | 61,980 | 61,980 | 85,510 | 85,510 | 85,510 |
| End Cash Position | 48,918 | 40,601 | 61,980 | 48,107 | 62,624 |
| Net Cash Flow | $-13,062 | $-21,379 | $-23,530 | $-37,403 | $-22,886 |
| Free Cash Flow | |||||
| Operating Cash Flow | -44,909 | -12,913 | -149,246 | -121,647 | -91,959 |
| Capital Expenditure | -159 | -9 | -386 | -386 | -143 |
| Free Cash Flow | -45,068 | -12,922 | -149,632 | -122,033 | -92,102 |